Bayer Stock Forecast for 2022 - 2025 - 2030
Updated on 05/19/2022
According to fourteen esteemed experts, the average price target for Bayer to reach this year is 76.00€, with a potential upside of approximately 19.12%. This prediction is based on a high estimate of 122.62€ and a low estimate of 55.00€. If you want to invest in BAYN stock, you might also want to take a look at how its competitors are doing.
19.12% Upside
Bayer Price Forecast for 2022 - 2025 - 2030
In the last three years, Bayer's Price has grown by 9.6%, rising from 57.62€ to 63.15€. For next year, analysts predict earnings per share of 65.08€, which would mean an increase of 3.06%. Over the next nine years, experts predict that Bayer's Price will grow at a rate of 20.88%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
5
|
$152.43 | $152.52 | 10.21% | 19 |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
7
|
$112.74 | $141.24 | 24.18% | 19 |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
3
|
£102.44 | £136.08 | 42.07% | 13 |
| COST Stock Forecast | Costco Wholesale | Outperform |
6
|
$429.40 | $595.76 | 38.57% | 12 |
| DHR Stock Forecast | Danaher | Outperform |
5
|
$243.60 | $339.17 | 37.52% | 7 |
Bayer Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Bayer's Revenue has grown by 19.97%, rising from 36742.00€ to 44081.00€. For next year, analysts predict earnings per share of 48030.66€, which would mean an increase of 8.96%. Over the next nine years, experts predict that Bayer's Revenue will grow at a rate of 77.63%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
8
|
$77.02 | $76.69 | 1.27% | 16 |
| AMGN Stock Forecast | Amgen | Hold |
8
|
$243.96 | $246.46 | 1.45% | 13 |
| DE Stock Forecast | Deere & | Outperform |
5
|
$368.67 | $409.08 | 20.84% | 17 |
Bayer Dividend per Share Forecast for 2022 - 2025 - 2030
In the past three years, Bayer's DPS has decreased by 28.57%, going from 2.80€ to only 2.00€. For next year, analysts predict earnings per share of 2.27€, which would mean an increase of 13.33%. Over the next nine years, experts predict that Bayer's DPS will grow at a rate of 154.8%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GlaxoSmithKline | Outperform |
1
|
£17.70 | £16.08 | 1.69% | 11 |
| CSL Stock Forecast | CSL | Outperform |
4
|
$266.28 | $228.01 | -14.01% | 10 |
| GILD Stock Forecast | Gilead Sciences | Outperform |
5
|
$63.22 | $75.96 | 9.14% | 19 |
Bayer Free Cash Flow Forecast for 2022 - 2025 - 2030
Bayer's Free Cash Flow have decreased by 53.46% in the past three years, from 5324.00€ to just 2478.00€. In the next year, analysts believe that Free Cash Flow will reach a reasonable 3536.02€ – an increase of 42.7%. For the next nine years, experts predict that Bayer's Free Cash Flow will grow at a rate of 698.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
5
|
$251.10 | $270.20 | 13.5% | 3 |
| CL Stock Forecast | Colgate-Palmolive | Hold |
4
|
$75.71 | $84.90 | 8.31% | 9 |
| DOW Stock Forecast | Dow | Outperform |
3
|
$68.91 | $64.10 | 7.39% | 11 |
Bayer Net Income Forecast for 2022 - 2025 - 2030
In the past three years, BAYN's Net Income has decreased from 1695.00€ to 1000.00€ – a 41% drop. For the following year, the 0 analysts predict that BAYN's Net Income will drop by 317.32%, reaching -16528.31€. In 2030, the professionals' prediction is that BAYN's Net Income will decrease by 1752.83%, reaching -16528.31€.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BAS Stock Forecast | BASF | Outperform |
5
|
49.86€ | 78.27€ | 28.36% | 16 |
| CTVA Stock Forecast | Corteva | Outperform |
1
|
$57.09 | $53.33 | 12.1% | 13 |
| BAX Stock Forecast | Baxter International | Outperform |
5
|
$72.12 | $92.47 | 24.79% | 3 |
Bayer EBITDA Forecast for 2022 - 2025 - 2030
Bayer's EBITDA has seen impressive growth in the last three years, rising from 7145.00€ to 8423.00€ – a growth of 17.89%. In the next year, analysts believe that EBITDA will reach a reasonable 10132.03€ – an increase of 20.29%. For the next nine years, the forecast is for EBITDA to grow by 225.13%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| GIVN Stock Forecast | Givaudan | Hold |
3
|
CHF4.04k | CHF4.11k | -0.97% | 15 |
| DD Stock Forecast | DuPont de Nemours | Outperform |
3
|
$64.28 | $98.25 | 36.9% | 7 |
| SGO Stock Forecast | Compagnie de Saint-Gobain | Outperform |
5
|
53.69€ | 71.19€ | 35.97% | 9 |
Bayer EBIT Forecast for 2022 - 2025 - 2030
In the past three years, Bayer's EBIT has grown by 68.01%, rising from 4257.00€ to 7152.00€. For the next year, analysts predict that EBIT will reach 8139.69€ – an increase of 13.81%. Over the next nine years, experts believe that BAYN's EBIT will grow at a rate of 80%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen | Outperform |
4
|
$195.71 | $287.21 | 16.24% | 24 |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
2
|
¥1.80k | ¥0.00 | 33.33% | 0 |
| BEI Stock Forecast | Beiersdorf | Outperform |
4
|
95.16€ | 102.71€ | 11.39% | 13 |
Bayer EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Bayer's EPS has grown by 9.6%, rising from 5.94€ to 6.51€. For next year, analysts predict earnings per share of 6.71€, which would mean an increase of 3.06%. Over the next nine years, experts predict that Bayer's EPS will grow at a rate of 20.88%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| CHD Stock Forecast | Church & Dwight | Hold |
5
|
$90.19 | $88.52 | 10.88% | 9 |
| 1301 Stock Forecast | Formosa Plastics | Outperform |
6
|
NT$104.50 | NT$125.45 | 24.88% | 0 |
| GMAB Stock Forecast | Genmab A/S | Outperform |
5
|
kr2.22k | kr2.84k | 24% | 13 |